Form 4: Puma Biotechnology CEO Sells Shares Under Pre-Arranged Trading Plan

Puma Biotechnology's President and CEO, Alan H. Auerbach, sold a total of 47,172 shares of common stock in early July 2025 under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Alan H. Auerbach, who serves as President and CEO, Director, and a 10% Owner of Puma Biotechnology, Inc. (PBYI), reported transactions.
• Transactions involved the sale of common stock on two separate dates: July 8, 2025, and July 9, 2025.
• On July 8, 2025, 25,592 shares were sold at a price of $3.533 per share.
• On July 9, 2025, an additional 21,580 shares were sold at a price of $3.535 per share.
• The total number of shares sold across both transactions was 47,172.
• These sales were executed pursuant to a Rule 10b5-1(c) trading plan, which was adopted on December 17, 2020.
• Following these reported transactions, Alan H. Auerbach directly beneficially owns 7,180,901 shares of Puma Biotechnology common stock.

Sentiment

Score: 5

Explanation: The document reports routine insider stock sales conducted under a pre-arranged 10b5-1 plan, which is a neutral event for market sentiment as it indicates planned personal financial management rather than a reaction to new company developments.

Positives

• The transactions were conducted under a pre-arranged Rule 10b5-1 trading plan, indicating planned personal financial management rather than a reaction to new company developments, which enhances transparency and reduces concerns about opportunistic trading.

Negatives

• President and CEO Alan H. Auerbach sold a significant number of shares (47,172 shares) of company stock, which, despite being under a 10b5-1 plan, can sometimes be perceived by the market as a lack of confidence.

Risks

• Potential for negative market perception of insider selling, which, even when conducted under a 10b5-1 plan, could be misinterpreted as a signal of reduced confidence in the company's future prospects.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Industry Context

This insider transaction report is specific to Puma Biotechnology, Inc. and does not provide broader industry trends or competitive analysis.

Stakeholder Impact

• Shareholders may interpret the sales as a signal, though the pre-arranged nature of the 10b5-1 plan mitigates potential negative interpretations, suggesting the sales are for personal financial planning rather than a reflection of company performance.

Key Dates

Recommendation

Keywords

PBYI, Puma Biotechnology, Alan H. Auerbach, Form 4, insider trading, stock sale, CEO, 10b5-1 plan, common stock